Daniel Couriel, MD
Hematology & Oncology · Salt Lake City, UTNPI 1275627309
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.8%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Seagen Inc. at 47.8% of the total. Reporting peaked in 2021 at $51,785 and has fallen 77.1% since, to $11,866 in 2025. Among hematology & oncology clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 161 payments — averaging $1425.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$110K
- Pfizer$38K
- Incyte Corporation$33K
- Mallinckrodt Hospital Products Inc.$14K
- Sanofi-aventis U.S. LLC$11K
- Sanofi$10K
- plus $13K from 10 others
Across 7 payments — averaging $11,240 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Syndax Pharmaceuticals, Inc.$66K
- Incyte Corporation$6K
- Pharmacyclics LLC, An Abbvie Company$6K
What the payments were for
- Consulting fees$71,42131%
- Speaking & faculty fees$132,65058%
- Travel & lodging$21,3589%
- Food & beverage$3,9102%
- Education$1050%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Seagen Inc. | 69 | $109,623 |
| Pfizer | 22 | $37,915 |
| Incyte Corporation | 27 | $32,860 |
| Mallinckrodt Hospital Products Inc. | 6 | $14,051 |
| Sanofi-aventis U.S. LLC | 5 | $11,214 |
| Sanofi | 4 | $10,435 |
| Gilead | 11 | $5,894 |
| Jazz Pharmaceuticals Inc. | 6 | $3,727 |
| Merck | 1 | $2,135 |
| Astellas Pharma US Inc | 2 | $1,143 |
| Novartis | 3 | $177 |
| Beigene USA, Inc. | 1 | $117 |
| Bristol Myers Squibb | 1 | $60 |
| Janssen Scientific Affairs, LLC | 1 | $52 |
| Menarini Silicon Biosystems, Inc. | 1 | $23 |
| Iovance Biotherapeutics, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$229,444 in reported general payments places this provider in the 95th percentile of 77 hematology & oncology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 33 | $443,398 |
| RezurockBelumosudil Mesylate | 19 | $393,821 |
| XospataGilteritinib Fumarate | 11 | $313,567 |
| Ursodiol | 40 | $2,200 |
| Acyclovir | 72 | $1,231 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 28 | $264 |
| Omeprazole | 40 | $253 |
| Potassium Chloride | 14 | $195 |
| Tamsulosin Hcl | 25 | $101 |
| Famotidine | 11 | $76 |
| Penicillin V Potassium | 14 | $71 |
| Prednisone | 12 | $68 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $32,860 | $443,39833 claims |
| Sanofi-aventis U.S. LLCRezurock | $11,214 | $393,82119 claims |
| Astellas Pharma US IncXospata | $1,143 | $313,56711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 77 hematology & oncology providers in Utah.
Other hematology & oncology in Salt Lake City
- Douglas SborovSalt Lake City$473K
- Shiven PatelSalt Lake City$223K
- Neeraj AgarwalSalt Lake City$159K
- Benjamin MaughanSalt Lake City$142K
- Schickwann TsaiSalt Lake City$137K
- Heloisa SoaresSalt Lake City$111K
- Daanish HodaSalt Lake City$80K
- Tsewang TashiSalt Lake City$69K
- Finn PetersenSalt Lake City$51K
- Anna ChalmersSalt Lake City$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.